CAR-T Cell Therapy and Expectations

Chimeric antigen receptor (CAR) T-cell therapy can be an acceptabletreatment for HCS and malignancies of immune system cells. Car T- celltherapy has shown to sustain remissions in patients with refractory or inone’s with relapsed B-cell malignancy. But clinically we have not seenthese developments in solid tumors. Cause in solid tumors with CAR-t celltherapy we are facing with immune-suppressive tumor TME that it mayrecruit regulatory T-CELLS and TAMs and MDSCs that three of these canact as an inhibitory for car-t cells therapy and also malignant cells candirectly express these four ligands such as CTLA۴, PD-۱, LAG-۳, TLM-۳on tumor infiltering lymphocytes and block the car-t cell activity. We knowthe major problem in patients with relapses CD۱۹ negative can cure withimmunotherapy CD۱۹. Now with OAD (oncolytic adenoviruses) Perhapswe are able to decrease the challenges of CAR-T cells therapy in TMEthroughout selectively, infection, replicating in malignant cells. On theother hand, we have BiTE that they are a kind of anti-cancer drug withFDA approval for ALL that BiTE therapy has some problems for solidtumors that finally can lead to increased toxicities inpatients. Conclusion: a new generation of OAD-BiTE can activate andproliferation T cells upon infection of cancer cells so a combination of car-tcell therapy and an OAD-BiTE has the potential to overcome the limitationof CARs and BiTEs in solid tumors.

Keywords:

CAR-t cell therapy , BiTE , OAD , Malignancy , CD۱۹